Company: NCEL
Filing Date: 2025-10-24
Form Type: POS AM
Source: 0001213900-25-102149
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-10-24
Form: POS AM
Chunk 2
---
 securities are being registered
under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the Registration
Statement.

The information in this preliminary prospectus is not complete and may be changed. The Selling Shareholder may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

<div align='center'>Up to 5,000,000 Common Shares

NLS Pharmaceutics Ltd.</div>

This prospectus relates
to the offer and sale of up to 5,000,000 of our common shares, 0.03 Swiss Franc (CHF) par value per share (the “Common Shares”),
by Alpha Capital Anstalt, a Liechtenstein Anstalt (“Alpha, or the “Selling Shareholder”).

On March 31, 2025, we
entered into a Common Share Purchase Agreement (the “Purchase Agreement”), with the Selling Shareholder, which provided for
the sale of up to $25.0 million of our Common Shares. Of the $25.0 million eligible to be sold pursuant to the Purchase Agreement (the
“Total Commitment”), to date we have not sold any Common Shares. In connection with the Purchase Agreement, we may request
pre-paid advances of the Total Commitment, in an amount up to $25.0 million. In connection with the Purchase Agreement, we also agreed
to issue the Selling Shareholder $250,000 in Common Shares (the “Commitment Shares”), and as such we issued the Selling Shareholder
a pre-funded warrant to purchase 192,308 Common Shares as Commitment Shares.

The Common Shares being offered
by the Selling Shareholder may be issued pursuant to the Purchase Agreement. We are not selling any securities under this prospectus and
will not receive any of the proceeds from the sale of our Common Shares by the Selling Shareholder. However, we may receive up to $25.0
million in aggregate gross proceeds from sales of our Common Shares to the Selling Shareholder that we may make under the Purchase Agreement,
from time-to-time after the date of this prospectus. The additional Common Shares that may be offered pursuant to this prospectus would
be purchased by the Selling Shareholder pursuant to the Purchase Agreement at ninety-five percent (95%) of the lesser of the (